Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs), announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the event, President and CEO Abizer Gaslightwala shared insights about his career journey, his commitment to the company, and his enthusiasm for Akari's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.
Akari Therapeutics (NASDAQ: AKTX), un'azienda biotecnologica oncologica specializzata nello sviluppo di nuovi coniugati anticorpo-farmaco (ADC) con carichi immuno-oncologici innovativi, ha annunciato la sua partecipazione alla conferenza virtuale per investitori "What's Your Story" Summer Spotlight On-Demand.
Durante l'evento, il Presidente e CEO Abizer Gaslightwala ha condiviso approfondimenti sul suo percorso professionale, il suo impegno verso l'azienda e il suo entusiasmo per i programmi di sviluppo di Akari. La presentazione è ora disponibile on-demand su virtualinvestorco.com e sul sito web delle relazioni con gli investitori dell'azienda.
Akari Therapeutics (NASDAQ: AKTX), una empresa biotecnológica oncológica enfocada en el desarrollo de nuevos conjugados anticuerpo-fármaco (ADC) con cargas inmuno-oncológicas innovadoras, anunció su participación en la conferencia virtual para inversores "What's Your Story" Summer Spotlight On-Demand.
Durante el evento, el Presidente y CEO Abizer Gaslightwala compartió detalles sobre su trayectoria profesional, su compromiso con la empresa y su entusiasmo por los programas de desarrollo de Akari. La presentación ya está disponible bajo demanda en virtualinvestorco.com y en el sitio web de relaciones con inversores de la compañía.
Akari Therapeutics (NASDAQ: AKTX)는 혁신적인 면역항암제 페이로드 항체 약물 접합체(ADC) 개발에 주력하는 종양학 바이오테크 기업으로, 가상 투자자 컨퍼런스 "What's Your Story" Summer Spotlight On-Demand에 참여한다고 발표했습니다.
행사에서 사장 겸 CEO 아비저 가슬라이트왈라는 자신의 경력 여정, 회사에 대한 헌신, Akari의 개발 프로그램에 대한 열정을 공유했습니다. 해당 발표는 현재 virtualinvestorco.com과 회사 투자자 관계 웹사이트에서 온디맨드로 시청할 수 있습니다.
Akari Therapeutics (NASDAQ : AKTX), une société biotechnologique en oncologie spécialisée dans le développement de conjugués anticorps-médicaments (ADC) innovants à charge immuno-oncologique, a annoncé sa participation à la conférence virtuelle pour investisseurs "What's Your Story" Summer Spotlight On-Demand.
Lors de l'événement, le Président-directeur général Abizer Gaslightwala a partagé des perspectives sur son parcours professionnel, son engagement envers l'entreprise et son enthousiasme pour les programmes de développement d'Akari. La présentation est désormais accessible à la demande sur virtualinvestorco.com ainsi que sur le site des relations investisseurs de la société.
Akari Therapeutics (NASDAQ: AKTX), ein biotechnologisches Onkologieunternehmen, das sich auf die Entwicklung neuartiger immunonkologischer Wirkstoff-Antikörper-Konjugate (ADCs) spezialisiert hat, gab seine Teilnahme an der virtuellen Investorenkonferenz "What's Your Story" Summer Spotlight On-Demand bekannt.
Während der Veranstaltung teilte Präsident und CEO Abizer Gaslightwala Einblicke in seinen beruflichen Werdegang, sein Engagement für das Unternehmen und seine Begeisterung für die Entwicklungsprogramme von Akari. Die Präsentation ist jetzt on-demand über virtualinvestorco.com und die Investor-Relations-Website des Unternehmens verfügbar.
- None.
- None.
Video webcast now available on-demand
BOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced Abizer Gaslightwala, Director, President and Chief Executive Officer of Akari, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference.
As part of the event, Mr. Gaslightwala dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company’s programs in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Presentations page in the Investors section of the Company’s website (akaritx.com).
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing inhibition has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
FAQ
When did Akari Therapeutics (AKTX) participate in the Virtual Investor Summer Spotlight Conference?
Where can investors watch Akari Therapeutics' (AKTX) Virtual Investor Conference presentation?
What did Akari Therapeutics' CEO discuss at the Virtual Investor Conference?
What type of therapeutics is Akari Therapeutics (AKTX) developing?
